BACKGROUND: The role of TP63 in cancer remains controversial since both oncogenic and tumor suppressive actions have been reported. p63 protein is found in the nuclei of basal cells of the normal prostate, yet it is absent in the vast majority of prostate cancer nuclei. Since a complex array of TP63 mRNA transcripts encode polypeptides with distinct functional properties, it is important to determine which forms are expressed in normal and prostate cancer tissue. METHODS: We used real-time RT-PCR to distinguish TP63 mRNA isoforms in prostate cancer cell lines (n = 7), and samples from prostate cancer patients. We sequenced all TP63 exons from 20 primary tumors, 20 metastases, 28 tumor xenografts, and 7 prostate cancer cell lines. RESULTS: TP63 mRNA isoforms were present in all tumors, albeit at levels lower than in normal prostate. The most abundant N-terminal variant was DeltaN; the most abundant C-terminal variant was the alpha form. The prostate tumor cell line CWR22Rv1 contained a single G to T substitution in exon 8 that is identical to a dominant-negative DNA binding inactivation mutation occurring in patients with a congenital TP63 deficiency syndrome. One patient tumor contained a somatic mutation in exon 11. CONCLUSIONS: The pattern of TP63 mRNA expression in normal prostate tissue is retained in reduced amounts in prostate cancer, and a potentially functional TP63 mutation was identified in one prostate tumor. Thus, if TP63 is a prostate cancer gene it likely functions as a tumor suppressor. Further study of the role of TP63 isoforms in regulating stem cell functions of normal and neoplastic prostate epithelial cells is needed. Prostate 69:559-569, 2009. (c) 2009 Wiley-Liss, Inc.
BACKGROUND: The role of TP63 in cancer remains controversial since both oncogenic and tumor suppressive actions have been reported. p63 protein is found in the nuclei of basal cells of the normal prostate, yet it is absent in the vast majority of prostate cancer nuclei. Since a complex array of TP63 mRNA transcripts encode polypeptides with distinct functional properties, it is important to determine which forms are expressed in normal and prostate cancer tissue. METHODS: We used real-time RT-PCR to distinguish TP63 mRNA isoforms in prostate cancer cell lines (n = 7), and samples from prostate cancer patients. We sequenced all TP63 exons from 20 primary tumors, 20 metastases, 28 tumor xenografts, and 7 prostate cancer cell lines. RESULTS: TP63 mRNA isoforms were present in all tumors, albeit at levels lower than in normal prostate. The most abundant N-terminal variant was DeltaN; the most abundant C-terminal variant was the alpha form. The prostate tumor cell line CWR22Rv1 contained a single G to T substitution in exon 8 that is identical to a dominant-negative DNA binding inactivation mutation occurring in patients with a congenital TP63 deficiency syndrome. One patient tumor contained a somatic mutation in exon 11. CONCLUSIONS: The pattern of TP63 mRNA expression in normal prostate tissue is retained in reduced amounts in prostate cancer, and a potentially functional TP63 mutation was identified in one prostate tumor. Thus, if TP63 is a prostate cancer gene it likely functions as a tumor suppressor. Further study of the role of TP63 isoforms in regulating stem cell functions of normal and neoplastic prostate epithelial cells is needed. Prostate 69:559-569, 2009. (c) 2009 Wiley-Liss, Inc.
Authors: J Celli; P Duijf; B C Hamel; M Bamshad; B Kramer; A P Smits; R Newbury-Ecob; R C Hennekam; G Van Buggenhout; A van Haeringen; C G Woods; A J van Essen; R de Waal; G Vriend; D A Haber; A Yang; F McKeon; H G Brunner; H van Bokhoven Journal: Cell Date: 1999-10-15 Impact factor: 41.582
Authors: Adeboye O Osunkoya; Donna E Hansel; Xinlai Sun; George J Netto; Jonathan I Epstein Journal: Am J Surg Pathol Date: 2008-03 Impact factor: 6.394
Authors: G Pellegrini; E Dellambra; O Golisano; E Martinelli; I Fantozzi; S Bondanza; D Ponzin; F McKeon; M De Luca Journal: Proc Natl Acad Sci U S A Date: 2001-03-13 Impact factor: 11.205
Authors: Sanjay M Mallya; H Irene Wu; Elizabeth A Saria; Kristin R Corrado; Andrew Arnold Journal: J Bone Miner Res Date: 2010-07-16 Impact factor: 6.741
Authors: Jan Roger Olsen; Anne Margrete Oyan; Kari Rostad; Margrete R Hellem; Jie Liu; Lisha Li; David R Micklem; Hallvard Haugen; James B Lorens; Varda Rotter; Xi-Song Ke; Biaoyang Lin; Karl-Henning Kalland Journal: PLoS One Date: 2013-05-01 Impact factor: 3.240
Authors: Laura E Pascal; Yao Wang; Mingming Zhong; Dan Wang; Anish Bhaswanth Chakka; Zhenyu Yang; Feng Li; Qiong Song; Lora H Rigatti; Srilakshmi Chaparala; Uma Chandran; Anil V Parwani; Zhou Wang Journal: Neoplasia Date: 2018-03-06 Impact factor: 5.715
Authors: Hsueh-Li Tan; Michael C Haffner; David M Esopi; Ajay M Vaghasia; Giovanna A Giannico; Hillary M Ross; Susmita Ghosh; Jessica L Hicks; Qizhi Zheng; Ankur R Sangoi; Srinivasan Yegnasubramanian; Adeboye O Osunkoya; Angelo M De Marzo; Jonathan I Epstein; Tamara L Lotan Journal: Mod Pathol Date: 2014-09-12 Impact factor: 7.842